This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Novo Nordisk A/S
Drug Names(s): NN1218, ultra fast-acting insulin aspart
Description: NN1218 is an ultra-fast-acting insulin analogue intended to provide faster onset of action than the currently available fast-acting insulin analogues. It is a faster acting formulation of insulin aspart, using well known excipients: nicotinamide, an absorption modifier, and L-arginine, a stability enhancer.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: